Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter M Ravdin

Showing results (11-20 of 38) with videos related to

Pageof 4
Sort By:
Medical Decision Making : an International Journal of the Society for Medical Decision Making|June 14, 2005
Decreased use of adjuvant breast cancer therapy in a randomized controlled trial of a decision aid with individualized risk informationPamela B Peele, Laura A Siminoff, Ying Xu, et al.
Psycho-Oncology|March 3, 2006
A decision aid to assist in adjuvant therapy choices for breast cancerLaura A Siminoff, Nahida H Gordon, Paula Silverman, et al.
The Lancet. Oncology|February 16, 2010
Ki67 in breast cancer: prognostic and predictive potentialRinat Yerushalmi, Ryan Woods, Peter M Ravdin, et al.
Journal of Oncology Practice|December 15, 2018
Communicating Risks of Adjuvant Chemotherapy for Breast Cancer: Getting Beyond the Laundry ListEden R Brauer, Elisa F Long, Joy Melnikow, et al.
The Oncologist|April 7, 2009
The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicineJeffrey S Ross, Elzbieta A Slodkowska, W Fraser Symmans, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 2, 2008
Prediction model for estimating the survival benefit of adjuvant radiotherapy for gallbladder cancerSamuel J Wang, C David Fuller, Jong-Sung Kim, et al.
The New England Journal of Medicine|April 20, 2007
The decrease in breast-cancer incidence in 2003 in the United StatesPeter M Ravdin, Kathleen A Cronin, Nadia Howlader, et al.
Breast Cancer Research and Treatment|April 28, 2004
A Southwest Oncology Group Randomized Phase II Study of doxorubicin and paclitaxel as frontline chemotherapy for women with metastatic breast cancerGary H Lyman, Stephanie J Green, Peter M Ravdin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 19, 2005
Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102Laura F Hutchins, Stephanie J Green, Peter M Ravdin, et al.
Journal of the National Cancer Institute|February 26, 2011
Independent prognostic value of screen detection in invasive breast cancerStella Mook, Laura J Van 't Veer, Emiel J Rutgers, et al.
Pageof 4

Showing results (11-20 of 38) with videos related to

Sort By:
Pageof 4
Medical Decision Making : an International Journal of the Society for Medical Decision Making|June 14, 2005
Decreased use of adjuvant breast cancer therapy in a randomized controlled trial of a decision aid with individualized risk informationPamela B Peele, Laura A Siminoff, Ying Xu, et al.
Psycho-Oncology|March 3, 2006
A decision aid to assist in adjuvant therapy choices for breast cancerLaura A Siminoff, Nahida H Gordon, Paula Silverman, et al.
The Lancet. Oncology|February 16, 2010
Ki67 in breast cancer: prognostic and predictive potentialRinat Yerushalmi, Ryan Woods, Peter M Ravdin, et al.
Journal of Oncology Practice|December 15, 2018
Communicating Risks of Adjuvant Chemotherapy for Breast Cancer: Getting Beyond the Laundry ListEden R Brauer, Elisa F Long, Joy Melnikow, et al.
The Oncologist|April 7, 2009
The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicineJeffrey S Ross, Elzbieta A Slodkowska, W Fraser Symmans, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 2, 2008
Prediction model for estimating the survival benefit of adjuvant radiotherapy for gallbladder cancerSamuel J Wang, C David Fuller, Jong-Sung Kim, et al.
The New England Journal of Medicine|April 20, 2007
The decrease in breast-cancer incidence in 2003 in the United StatesPeter M Ravdin, Kathleen A Cronin, Nadia Howlader, et al.
Breast Cancer Research and Treatment|April 28, 2004
A Southwest Oncology Group Randomized Phase II Study of doxorubicin and paclitaxel as frontline chemotherapy for women with metastatic breast cancerGary H Lyman, Stephanie J Green, Peter M Ravdin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 19, 2005
Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102Laura F Hutchins, Stephanie J Green, Peter M Ravdin, et al.
Journal of the National Cancer Institute|February 26, 2011
Independent prognostic value of screen detection in invasive breast cancerStella Mook, Laura J Van 't Veer, Emiel J Rutgers, et al.
Pageof 4